Home
/
AXIM BIOTECHNOLOGIES, INC.
/
Financials
/
Quarterly
AXIM BIOTECHNOLOGIES, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AXIM BIOTECHNOLOGIES, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Jun 30, 2024
$17.5K
Aug 19, 2024
Q1
2024
Mar 31, 2024
$53.0K
May 22, 2024
Q3
2023
Sep 30, 2023
$9.6K
Nov 20, 2023
Q2
2024
Jun 30, 2023
$9.9K
Aug 19, 2024
Q1
2024
Mar 31, 2023
$7.4K
May 22, 2024
Q3
2023
Sep 30, 2022
$1.3K
Nov 20, 2023
Q2
2022
Jun 30, 2022
$0
Aug 16, 2022
Q1
2023
Mar 31, 2022
$0
May 22, 2023
Q3
2022
Sep 30, 2021
$8.1K
Nov 15, 2022
Q2
2022
Jun 30, 2021
$14.9K
Aug 16, 2022
Q1
2022
Mar 31, 2021
$32.6K
May 23, 2022
Q3
2021
Sep 30, 2020
$0
Nov 22, 2021
Q2
2020
Jun 30, 2020
$0
Aug 18, 2020
Q1
2021
Mar 31, 2020
$0
Jun 2, 2021
Q3
2020
Sep 30, 2019
$0
Nov 27, 2020
Q2
2020
Jun 30, 2019
$0
Aug 18, 2020
Q1
2020
Mar 31, 2019
$17.1K
Jul 2, 2020
Q3
2019
Sep 30, 2018
$6.2K
Nov 14, 2019
Q2
2019
Jun 30, 2018
$8.2K
Aug 14, 2019
Q1
2019
Mar 31, 2018
$14.2K
May 15, 2019
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2014
Jun 30, 2014
$7.5K
Aug 26, 2014
Q3
2014
Sep 30, 2013
$10.8K
Nov 14, 2014
Q2
2014
Jun 30, 2013
$10.8K
Aug 26, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Jun 30, 2024
($2.27M)
Aug 19, 2024
Q1
2024
Mar 31, 2024
($292.3K)
May 22, 2024
Q2
2024
Mar 31, 2024
($292.3K)
Aug 19, 2024
Q3
2023
Sep 30, 2023
$328.5K
Nov 20, 2023
Q2
2024
Jun 30, 2023
($3.72M)
Aug 19, 2024
Q3
2023
Jun 30, 2023
($3.72M)
Nov 20, 2023
Q1
2024
Mar 31, 2023
($2.76M)
May 22, 2024
Q2
2024
Mar 31, 2023
($2.76M)
Aug 19, 2024
Q3
2023
Mar 31, 2023
($2.76M)
Nov 20, 2023
Q3
2023
Sep 30, 2022
($2.03M)
Nov 20, 2023
Q3
2023
Jun 30, 2022
($1.22M)
Nov 20, 2023
Q2
2023
Jun 30, 2022
($1.22M)
Aug 21, 2023
Q2
2022
Mar 31, 2022
($2.09M)
Aug 16, 2022
Q3
2023
Mar 31, 2022
($2.09M)
Nov 20, 2023
Q1
2023
Mar 31, 2022
($2.09M)
May 22, 2023
Q3
2022
Sep 30, 2021
($3.29M)
Nov 15, 2022
Q2
2022
Jun 30, 2021
($3.83M)
Aug 16, 2022
Q3
2022
Jun 30, 2021
($3.83M)
Nov 15, 2022
Q3
2022
Mar 31, 2021
($864.5K)
Nov 15, 2022
Q1
2022
Mar 31, 2021
($864.5K)
May 23, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Jun 30, 2024
($569.4K)
Aug 19, 2024
Q1
2024
Mar 31, 2024
($401.6K)
May 22, 2024
Q3
2023
Sep 30, 2023
($588.5K)
Nov 20, 2023
Q2
2024
Jun 30, 2023
($697.7K)
Aug 19, 2024
Q1
2024
Mar 31, 2023
($710.6K)
May 22, 2024
Q3
2023
Sep 30, 2022
($1.32M)
Nov 20, 2023
Q2
2023
Jun 30, 2022
($1.06M)
Aug 21, 2023
Q1
2023
Mar 31, 2022
($1.13M)
May 22, 2023
Q3
2022
Sep 30, 2021
($3.28M)
Nov 15, 2022
Q2
2022
Jun 30, 2021
($2.18M)
Aug 16, 2022
Q1
2022
Mar 31, 2021
($868.0K)
May 23, 2022
Q3
2021
Sep 30, 2020
($1.30M)
Nov 22, 2021
Q2
2021
Jun 30, 2020
($662.9K)
Aug 23, 2021
Q1
2021
Mar 31, 2020
($688.7K)
Jun 2, 2021
Q3
2020
Sep 30, 2019
($483.7K)
Nov 27, 2020
Q2
2020
Jun 30, 2019
($583.4K)
Aug 18, 2020
Q1
2020
Mar 31, 2019
($2.29M)
Jul 2, 2020
Q3
2019
Sep 30, 2018
($935.8K)
Nov 14, 2019
Q2
2019
Jun 30, 2018
($1.34M)
Aug 14, 2019
Q1
2019
Mar 31, 2018
($2.04M)
May 15, 2019